Cognitive and behavioural impairment in Parkinson's disease.
D000978:Antiparkinson Agents / Q000627:therapeutic use; D003072:Cognition Disorders / Q000209:etiology*; D003704:Dementia / Q000453:epidemiology*; D018450:Disease Progression; D006801:Humans; D015994:Incidence; D016631:Lewy Bodies / Q000473:pathology; D008559:Memantine / Q000627:therapeutic use; D001523:Mental Disorders / Q000209:etiology*; D053860:Pallidotomy; D010300:Parkinson Disease / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology* / Q000601:surgery; D011618:Psychotic Disorders / Q000453:epidemiology; D012306:Risk; D012893:Sleep Wake Disorders / Q000453:epidemiology / Q000209:etiology; D014796:Visual Perception
D000978:Antiparkinson Agents; D008559:Memantine